Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Geovax Labs Inc (GOVX)

Geovax Labs Inc (GOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks BayStreet.ca - Tue Jan 27, 9:45AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...

ONCY : 0.8701 (-1.12%)
FHTX : 4.76 (+0.21%)
ORIC : 9.77 (-1.11%)
LLY : 963.33 (+3.07%)
GOVX : 1.1550 (+5.96%)
SLS : 4.93 (-0.40%)
Roth MKM Sticks to Their Buy Rating for GeoVax Labs (GOVX) Tipranks - Wed Oct 15, 2025

Roth MKM analyst Jonathan Aschoff maintained a Buy rating on GeoVax Labs today and set a price target of $14.00. The company’s shares closed yesterday at $0.56.Elevate Your Investing Strategy: Take advantage...

GOVX : 1.1550 (+5.96%)
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities Newswire.ca - Wed Jul 16, 2025

/CNW/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is...

ONCY : 0.8701 (-1.12%)
ZLAB : 21.54 (-0.46%)
GOVX : 1.1550 (+5.96%)
SLS : 4.93 (-0.40%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.6100 (-5.29%)
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities PR Newswire - Wed Jul 16, 2025

Equity Insider News Commentary

ONCY : 0.8701 (-1.12%)
ZLAB : 21.54 (-0.46%)
GOVX : 1.1550 (+5.96%)
SLS : 4.93 (-0.40%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.6100 (-5.29%)
ZAILF : N/A (N/A)
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation BayStreet.ca - Thu Feb 27, 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...

ONCY : 0.8701 (-1.12%)
ZNTL : 4.09 (+2.00%)
NYT : 78.72 (-0.39%)
ABSI : 4.92 (-1.11%)
GOVX : 1.1550 (+5.96%)
ONC.TO : 1.42 (+2.16%)
GSK : 51.61 (-1.34%)
New Vaccine Technologies Lead the Charge as Global Immunization Efforts Evolve BayStreet.ca - Wed Dec 18, 2024

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...

PCVX : 56.93 (-0.54%)
BVAXF : 0.0509 (-3.60%)
BIOV.CN : 0.0600 (unch)
GILD : 131.65 (+0.62%)
GOVX : 1.1550 (+5.96%)
ARCT : 8.63 (+0.12%)
GeoVax Labs, Inc. Secures U.S. Patent Notice of Allowance for Tumor Immunotherapy Technology Quiver Quantitative, Inc. - Mon Dec 9, 2024

GeoVax Labs receives patent allowance, enhancing its intellectual property for cancer immunotherapy using its unique viral vector platform.Quiver AI SummaryGeoVax Labs, Inc. announced that the U.S. Patent...

GOVX : 1.1550 (+5.96%)
GeoVax Labs, Inc. CEO David Dodd to Present at NobleCon20 Conference Quiver Quantitative, Inc. - Tue Nov 26, 2024

GeoVax Labs announces CEO David Dodd will present at NobleCon20 on corporate updates and clinical trials.Quiver AI SummaryGeoVax Labs, Inc., a biotechnology company focused on human vaccines and cancer...

GOVX : 1.1550 (+5.96%)
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks Stocktwits - Fri Nov 22, 2024

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement.

SIGA : 4.60 (unch)
EBS : 8.47 (+2.92%)
GOVX : 1.1550 (+5.96%)
CMRX : 8.54 (-0.12%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth FinancialNewsMedia - Thu Jun 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

ONCY : 0.8701 (-1.12%)
AZN : 184.74 (-1.40%)
MRK : 112.16 (+2.73%)
GOVX : 1.1550 (+5.96%)
ONC.TO : 1.42 (+2.16%)
GSK : 51.61 (-1.34%)

Barchart Exclusives

McDonald’s Is Down 4% and Starbucks Is Up 25% in 2026. The Better Dividend Stock Might Surprise You. Barchart - Fri May 1, 6:00PM CDT
Starbucks is up 25% in 2026 while McDonald's slipped 4%. So why might McDonald's still be the smarter dividend buy? The numbers tell a story most investors are missing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.